Optimizing regulatory T cells for therapeutic application in human organ transplantation

Trishan Vaikunthanathan, Niloufar Safinia, Giovanna Lombardi

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


PURPOSE OF REVIEW: Initial clinical trials of adoptive regulatory T-cell (Treg) therapy in solid organ transplantation have proven to be both feasible and well tolerated. With Phase 2 trials underway, efforts have been focused on the optimization of the Treg product. RECENT FINDINGS: With science and our knowledge on the biology of these cells constantly advancing, we have been able to refine our search for a Treg population that would be ideally suited for therapeutic application. This idealized population must be readily isolated, allow for in-vitro expansion, demonstrate potent and specific suppressor function, maintain lineage stability and demonstrate a relevant homing profile. With the advent of innovative cell analysis/isolation techniques and genetic modifications, we are able to choose and design Tregs to fulfil these criteria. SUMMARY: By utilizing advances in science and technology, we can optimize Treg therapy in human organ transplantation maximizing their prospects in the arena of transplantation tolerance.

Original languageEnglish
Pages (from-to)516-523
Number of pages8
JournalCurrent Opinion in Organ Transplantation
Issue number5
Publication statusPublished - 1 Oct 2018


Dive into the research topics of 'Optimizing regulatory T cells for therapeutic application in human organ transplantation'. Together they form a unique fingerprint.

Cite this